
“I think it’s really important that people keep signing up to these type of trials to push research forward.”
This trial is looking at a new drug called TT-702 for . It is for people who have:
Solid tumours are any type of cancer apart from blood cancers such as leukaemia.
Cancer Research UK supports this trial.
Doctors are looking for new treatments for people with advanced cancer when other treatments have stopped working. In this trial they are looking to see if a drug called TT-702 might help.
TT-702 is a called a small molecule drug. It targets a receptor on cells called the A2B receptor. Cancer cells have more A2B receptors on their surface than normal cells. This causes the cancer cells to grow. It also helps the cancer to hide from the
.
When you take TT-702 it changes into a more active form of the drug called TT-478. TT-478 targets and blocks the A2B receptor. This causes the cancer cell to die. Researchers also hope it will kick start your immune system to find and kill cancer cells.
This trial is in 2 parts. Part 1 is looking at the best dose of TT-702. This part is open for people to join.
Part 2 will test this dose in a larger number of people. This part of the trial isn’t open yet.
This is the first time people are having TT-702.
The main aims of the trial are to find out:
Please note, the trial team also plan to look at TT-702 in combination with other treatments such as immunotherapy. We plan to add information about these groups when they open.
The following bullet points are a summary of the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.
Who can take part
You may be able to join this trial if all of the following apply. You:
As well as the above, you may be able to join part 2 if you have one of the following:
There are specific entry conditions for each of these three groups in part 2. The trial team will check these to see if you are suitable to join part 2 of the trial when it opens. |
Who can’t take part
Cancer related
You cannot join this trial if any of these apply. You:
Medical conditions
You cannot join this trial if any of these apply. You:
Other
You can’t join this trial if any of these apply. You:
This phase 1/2 trial is taking place in the UK. There are 2 parts. Part 1 is looking at the best dose of TT-702 to have. Part 2 is testing this dose in more people.
Part 1 (dose expansion part) – this is open
The team need 24 people to join part 1. The first few people taking part have a low dose of TT-702. The next few people have a higher dose if they didn’t have any serious side effects. And so on, until they find the best dose. This is a dose escalation trial.
Part 2 (dose expansion part) – this isn’t open yet
The team need 90 people to join part 2. When they find the best dose in part 1 then part 2 can begin. This part tests the best dose in a larger number of people. There are 3 groups:
Everyone in part 2 has the same dose of TT-702.
How you have treatment
TT-702 is a tablet. You take it once a day every day. You have treatment for up to a year as long as it is working and the side effects aren’t too bad.
The number of tablets you take depends on when you join the trial. You fill in a medication diary. You record when you take your tablets and how many you take.
On some of the days you attend the hospital, the team may ask you to bring your tablets in with you and take them when you are at your visit. This is likely to be on the days that you are having extra blood tests for research. The trial nurse will mark these days on your diary card.
You stop treatment if your cancer gets worse. The trial doctor will talk to you about other treatment options.
Blood and tissue samples for research
The team ask you to give some extra blood samples. Where possible, you have these at the same time as your routine blood tests.
They plan to use the samples to:
You don’t have to give all the extra samples if you don’t want to. You can still take part in the main trial.
Depending on when you join the trial you might need to give some extra tissue samples. The trial team will let you know if this applies to you.
You see the doctor and have some tests before you can take part. These include:
You have regular check ups with the trial doctor. At each visit you have some blood tests and a heart trace.
For the first few visits you’ll be at the hospital for most of the day. On the first day of treatment you may need to stay overnight. The rest of the hospital visits take about half a day.
Scans
You have a CT scan or an MRI scan every:
You also have a bone scan every 9 weeks if you have prostate cancer. You stop having these scans if your cancer gets worse.
Follow up
When you finish treatment you see the doctor 3 weeks later for a check up and some tests.
The team then follow you up every 3 months at a routine hospital appointment. Or they may call you at home to see how you are getting on. They might also check your hospital notes.
The trial team monitor you during treatment and afterwards. Contact your advice line or tell your doctor or nurse if any side effects are bad or not getting better.
As TT-702 is a new drug there may be side effects we don’t know about yet. The possible side effects include:
There is a small chance that TT-702 might make your skin more sensitive to the sun. The trial team recommend that you apply sunscreen and lip balm that is sun protection factor 30 (SPF30) or higher and avoid long periods out in the sun.
The trial doctor will talk to you about all the possible side effects of treatment.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Johann De Bono
Cancer Research UK
Teon Therapeutic
This is Cancer Research UK trial number CRUKD/21/005.
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
“I think it’s really important that people keep signing up to these type of trials to push research forward.”